PRECLINICAL DEVELOPMENT OF MONOCLONAL ANTIBODIES AND RELATED BIOLOGICALS: EMERGING TECHNOLOGIES AND NEW THERAPEUTIC CANDIDATES
134
Chapter 4 Fully tellurian monoclonal antibodies 138
Summary 138
Introduction 139
Technology platforms 139
Phage arrangement 139
MBAS 141
CBAS 142
HuCAL 142
MAbstract 142
ActivMAb 143
Adimab height 143
XenoMouse 143
UltiMAb 145
VelocImmune 145
Open Monoclonal Technology 146
Xenerex 146
SEBVI 147
Cloning a Human Response 147
Viventia platforms 147
Natural Human Antibodies 148
MabIgX 148
Reverse Translational Medicine 148
I-STAR 149
CellSpot 149
iBioLaunch 149
Case studies 150
Adimab 150
Acorda Therapeutics 150
Affitech 151
Agensys 153
Alopexx 153
AstraZeneca 154
BioFactura 155
Biotherapix 156
CellAct 156
Celldex 156
Centocor 157
Crucell 158
CSL 158
Dyax 158
Emergent BioSolutions 158
Functional Genetics 159
GenMab 159
Crucell 160
GSK 160
Humabs 160
Human Antibodomics 161
Humanyx 161
iBio 162
ImClone 162
IMED 163
Immune System Therapeutics 163
IQ Therapeutics 164
Kenta Biotech 164
Kyowa Hakko Kirin 165
MabVax 165
Mapp Biopharmaceutical 166
Medarex 166
MedImmune 167
Merck & Co 168
Micromet 169
MorphoSys 169
NatImmune 170
Neurimmune 170
NovImmune 170
Novo Nordisk 171
Omeros Corp 172
Oncaidia 172
OncoMed 172
Oxford BioTherapeutics 173
Panacea 173
Patrys 174
Peregrine 175
PharmAbcine 176
sanofi-aventis 176
Theraclone 177
Trellis Bioscience 178
U3 Pharma 178
Vaccinex 179
Vegenics 179
Xoma 180
Conclusions 189
Chapter 5 Antibody conjugates 192
Summary 192
Introduction 193
Technology platforms 193
Antibody Drug Conjugate 193
Targeted Antibody Payload 195
Probodies 195
Antibody cloaking 197
Targeted Photodynamic Therapy 197
AlbudAb 198
hyFc 198
Ligand traps 198
CovX-Body 200
Dynamic Cross-Linking 200
LEC record 200
Case studies 201
Algeta 201
Aphios 201
ArmaGen Technologies 201
Asan Medical Center 202
Bayer Schering 202
Beijing ABT 203
Biogen Idec 203
BioTransformations 203
Boehringer Ingelheim 204
Celldex 204
Cytoguide 205
CytomX 205
Dompe 206
EnGeneIC 206
FDA 206
Forerunner Pharma Research 207
Galileo Oncologics 207
Genentech 207
Genexine 208
ImmunoGen 208
Immunomedics 209
InNexus Biotech 210
Medarex 210
MedImmune 211
Merrimack 211
Morphotek 212
Mycenax 212
NCI 212
Oncaidia 213
OncoTherapy Science 213
Panacea 214
Peregrine 214
Pfizer 214
Pivotal BioSciences 215
Seattle Genetics 215
Symphogen 215
Transgene Biotek 216
Viventia 216
Conclusions 222
Chapter 6 Novel contracting molecules subsequent from antibodies 224
Summary 224
Introduction 225
Technology platforms 226
Fab 226
TetraMABs 227
scFv 227
Immuna 228
[scFv]2 228
BiTE 229
Avibodies 230
TandAb 233
Flexibody 234
V-NAR 234
Nanobody 236
Domain Antibodies 238
Heteropolymer 242
UniBody 243
Domain Exchanged Antibodies 244
SMIP 246
SCORPION 247
DVD-Ig 248
Case studies 249
Abbott Labs 249
Ablynx 249
AdAlta 250
Affimed 250
Avipep 251
Beijing ABT 251
Biogen Idec 252
Calmune 252
Elusys 253
ESBATech 253
Galileo Oncologics 253
Glycotope 254
GSK 254
Inmunova 255
MAT Biopharma 256
Micromet 256
Novartis 257
PharmAbcine 257
Trubion 257
Suzhou Stainwei Biotech 258
Taligen 259
Vegenics 259
Conclusions 264
Appendix 266
Primary investigate methodology 266
Glossary 267
Index 278
Read Also
Pages: 1 2
Tags: Antibodies, Biologicals, Candidates, Development, Emerging, Monoclonal, Preclinical, Related, technologies, Therapeutic